Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
26 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-10-17
Study Completion Date
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this study is to specifically examine changes in facial skin appearance after facial fat grafting with autologous fat tissue that has either been washed with sterile saline before injecting, or left unwashed. This will be testing two variations of a standard of care surgical procedure, in two cohorts of subjects. One group will receive washed fat, and one group will receive unwashed fat, to both sides of the face. There are no experimental devices, drugs, or biological agents being used in this study. All fat tissue is autologous from the subjects treated.
Significance: This study will provide evidence that may directly impact clinical practice for a common procedure in plastic surgery. Regardless of whether the null hypotheses is accepted or rejected, the data will be of direct clinical use and impact practice in the operating room.
Significance: This study will provide evidence that may directly impact clinical practice for a common procedure in plastic surgery. Regardless of whether the null hypotheses is accepted or rejected, the data will be of direct clinical use and impact practice in the operating room.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
NCT04559022
Acne Scars - Mixed Atrophic and Hypertrophic
Acne
COMPLETED
NA
Open Label, Multi-Center Study, Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Facial Fat Grafting
NCT05522426
Facial Atrophy and Loss of Contour
ACTIVE_NOT_RECRUITING
NA
The Use of Activated Platelet Rich Plasma (PRP) in Human Autologous Fat Transfer
NCT01461785
Lipofilling
Human Autologous Fat Transfer
COMPLETED
PHASE2/PHASE3
Autologous Adipose Cells Therapy
NCT06869252
Hair Loss/Baldness
Wrinkle Appearance
Volume
+5 more
RECRUITING
PHASE1/PHASE2
Dermal Fillers Patient Satisfaction
NCT01176812
Loss of Facial Fat
WITHDRAWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Autologous fat grafting is a very common standard of care procedure in plastic surgery, used for both aesthetic and reconstructive applications across the entire body.1 Facial fat grafting, in particular, is the most common site for use of autologous fat. The American Society of Plastic Surgeons (ASPS) statistics report showed 133,720 cases of facial fat grafting for cosmetic indications in 2020.2 This is mainly due to the fact that humans lose facial fat during the aging process, and that loss of volume leads to characteristic signs of aging.3 It is also well known that when autologous fat grafting is used for facial cosmetic injections, increasing the amount of fat in the dermal/subdermal region has very positive effects on the appearance of the skin.4-6 This is because adding more padding beneath the skin gives the appearance of suppleness and smoothness and mitigates the "deflated" appearance that patients complain of. Additionally, as the adipose graft tissue heals, it tends to increase vascularization in the region which also has a positive effect on the skin. This can improve fine and course wrinkles, and color tone and pigmentary variation can also improve.7-9 Facial fat grafting is commonly performed by surgeons at UPMC and throughout the Pittsburgh region, consistent with national practice patterns.
Autologous fat grafting is a minimally invasive procedure that involves harvest of fat tissue with a liposuction cannula. In many cases, the cannula is attached to a 10 mL syringe and negative pressure applied by withdrawing the syringe plunger during aspiration.1 In other cases, a mechanical aspiration machine is used to generate negative pressure.1 Either way, all of this equipment is standard in most operating rooms across the country. The aspirated material consists of small particles of adipose tissue, measuring between three and five mm in diameter.10 Once harvested into sterile vessels, the aspirate can be gently centrifuged or strained to separate and remove the aqueous and oil layers. If washed, a sterile saline solution would be used to perform the washing procedure. The material is often transferred between syringes using a Luer Lock connector and the graft material is then injected from syringes. Passing the tissue multiple times between Luer Lock connectors has become a very common method of breaking up clumps of tissue and enabling a more flowable graft material that can be injected through smaller gauge cannula without clogging.11
Controversy exists in the plastic surgery community as to the most beneficial preparation methods in the operating room.12 Different surgeons use a number of methods alone or in combination that include filtering or straining fat, gentle centrifugation, separation of fluid and oil layers by gravity, and rinsing/washing with sterile saline. All of these methods are well accepted as within standard of care and represent minimal manipulation of the tissue grafts. A national survey of the plastic surgery community, published by our group revealed that 28% of surgeons use a saline wash during their fat graft processing.13 The rationale for a saline wash is that it may decrease any residual free lipid/oil, as well as residual red cells, both of which can potentially cause irritation of the local tissues. However, opponents of washing often cite that there washing adds an extra step without clinical benefit.
Hypothesis: We hypothesize that a saline washed fat graft injectate will have improved appearance of facial skin. We speculate that the reduced free lipid and reduced red cell fraction will be beneficial in the healing process.
Significance: This study will provide evidence that may directly impact clinical practice for a common procedure in plastic surgery. Regardless of whether the null hypotheses is accepted or rejected, the data will be of direct clinical use and impact practice in the operating room.
Treatment Period: Autologous fat graft injections will be performed on Day 0 of the study period after eligibility determination has been made, and after baseline data collection. Subjects will be followed over a 12-month time period.
Autologous fat grafting is a minimally invasive procedure that involves harvest of fat tissue with a liposuction cannula. In many cases, the cannula is attached to a 10 mL syringe and negative pressure applied by withdrawing the syringe plunger during aspiration.1 In other cases, a mechanical aspiration machine is used to generate negative pressure.1 Either way, all of this equipment is standard in most operating rooms across the country. The aspirated material consists of small particles of adipose tissue, measuring between three and five mm in diameter.10 Once harvested into sterile vessels, the aspirate can be gently centrifuged or strained to separate and remove the aqueous and oil layers. If washed, a sterile saline solution would be used to perform the washing procedure. The material is often transferred between syringes using a Luer Lock connector and the graft material is then injected from syringes. Passing the tissue multiple times between Luer Lock connectors has become a very common method of breaking up clumps of tissue and enabling a more flowable graft material that can be injected through smaller gauge cannula without clogging.11
Controversy exists in the plastic surgery community as to the most beneficial preparation methods in the operating room.12 Different surgeons use a number of methods alone or in combination that include filtering or straining fat, gentle centrifugation, separation of fluid and oil layers by gravity, and rinsing/washing with sterile saline. All of these methods are well accepted as within standard of care and represent minimal manipulation of the tissue grafts. A national survey of the plastic surgery community, published by our group revealed that 28% of surgeons use a saline wash during their fat graft processing.13 The rationale for a saline wash is that it may decrease any residual free lipid/oil, as well as residual red cells, both of which can potentially cause irritation of the local tissues. However, opponents of washing often cite that there washing adds an extra step without clinical benefit.
Hypothesis: We hypothesize that a saline washed fat graft injectate will have improved appearance of facial skin. We speculate that the reduced free lipid and reduced red cell fraction will be beneficial in the healing process.
Significance: This study will provide evidence that may directly impact clinical practice for a common procedure in plastic surgery. Regardless of whether the null hypotheses is accepted or rejected, the data will be of direct clinical use and impact practice in the operating room.
Treatment Period: Autologous fat graft injections will be performed on Day 0 of the study period after eligibility determination has been made, and after baseline data collection. Subjects will be followed over a 12-month time period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Facial Skin Texture
Facial Skin Pigmentation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This study will include 2 cohorts, each consisting of approximately 13 subjects to undergo intervention, where each subject will have treatment of the skin of cheek area, upper lip, chin and superior neck regions, as well as the behind the ears with autologous fat graft. The subject will receive either a saline washed preparation or a non-washed preparation as determined by the randomization process. Autologous fat tissue will be harvested for the fat graft preparation (up to a maximum of 1 liter ) from the trunk or extremity donor site, consistent with standard clinical practice.
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Blinded grading based on VECTRA images and VISIA images will be performed on de-identified photography by a third-party vendor at the end of the study.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Autologous facial fat graft injection- washed fat
Washed fat injected into both the left and right sides of the face.
Group Type
OTHER
Autologous facial fat graft injection
Intervention Type
OTHER
Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
Autologous facial fat graft injection-unwashed fat
Unwashed fat injected into both the left and right sides of the face.
Group Type
OTHER
Autologous facial fat graft injection
Intervention Type
OTHER
Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous facial fat graft injection
Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ability to perform informed consent
2. Healthy female adults, from 35 to 70 years of age
3. Fitzpatrick Skin Type Scale scores \< 3.
4. FWAS-greater than moderate, equal to or greater than 4
5. Noticeable Physical signs of facial aging and sun damage including skin wrinkles, loss of elasticity and pigmentary changes, with greater than mild (≥4 on a 0 to 9 scale) signs of the following, per investigator discretion
1. Facial wrinkles (periorbital//periorbital//cheek)
2. Dyschromia (hyperpigmentation//uneven skin tone)
3. Rough skin texture (visual skin roughness//pore sizes)
6. Willingness to undergo the proposed treatment and comply with study procedures.
7. Negative pregnancy urine dip test (as indicated-unless s/p hysterectomy or past menopause documentation can be sourced to research chart.)
8. Willingness to avoid the use of laser, IPL, Botox (6 months), injectable fillers or other surgical cosmetic procedures on the face for 6 months ducts
9. Ability to produce sufficient fat tissue from donor site during harvest (up to a maximum of 1 liter)
2. Healthy female adults, from 35 to 70 years of age
3. Fitzpatrick Skin Type Scale scores \< 3.
4. FWAS-greater than moderate, equal to or greater than 4
5. Noticeable Physical signs of facial aging and sun damage including skin wrinkles, loss of elasticity and pigmentary changes, with greater than mild (≥4 on a 0 to 9 scale) signs of the following, per investigator discretion
1. Facial wrinkles (periorbital//periorbital//cheek)
2. Dyschromia (hyperpigmentation//uneven skin tone)
3. Rough skin texture (visual skin roughness//pore sizes)
6. Willingness to undergo the proposed treatment and comply with study procedures.
7. Negative pregnancy urine dip test (as indicated-unless s/p hysterectomy or past menopause documentation can be sourced to research chart.)
8. Willingness to avoid the use of laser, IPL, Botox (6 months), injectable fillers or other surgical cosmetic procedures on the face for 6 months ducts
9. Ability to produce sufficient fat tissue from donor site during harvest (up to a maximum of 1 liter)
Exclusion Criteria
1. Age \< 35 or \> 70 years of age
2. Any medical condition that would preclude safe administration of anesthesia and safe conduct of the adipose harvest procedure (such as an uncontrolled bleeding disorder or severe pulmonary disease), per investigator discretion.
3. Active infection on the face (e.g., acne, HSV (herpes simplex), etc.,) per investigator discretion.
4. Female in pregnancy (positive pregnancy-test performed before inclusion) or lactation or without effective contraception)
5. Received laser, IPL, botox (6 months), injectable fillers or other surgical cosmetic procedures on the face within 12 months of study consent and screening date. -prohibited for 6 months
6. Acutane use within past 12 months
7. Individuals with any contraindications of autologous lipografting, such as cutaneous rashes or infection in the area of intended fat harvest, lack of available donor fat, or other factors that, in the determination of the investigator, would be considered a contraindication.
8. Individuals diagnosed with known allergies to skin care products, topical antibiotics, adhesives, bandages, lidocaine, epinephrine, or other agents that might be used in the study
9. Individuals with any disease state or inappropriate physical skin condition (e.g., active/history of psoriasis, active eczema, excessive hair, scars, tattoos, etc. on face) that might impair evaluations or increase the health risk to the subject by participation in the opinion of the Investigator
10. Individuals with a history of immunosuppression/immune deficiency disorders/ known or suspected defect of healing (including HIV infection or AIDS)
11. Individuals with an uncontrolled disease such as hypertension, hyperthyroidism, or hypothyroidism, which may impact safety. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, which in the opinion of the Investigator, may create safety concerns or interfere with the study.
12. Individuals currently taking substances known to affect bleeding time, which in the opinion of the Investigator, may create safety concerns or interfere with the study (e.g., aspirin, Heparin, Warfarin, Plavix, supplements, etc.).
13. Individuals currently and chronically taking substances known to impair the immune system at doses anticipate to have a systemic effect on wound healing (e.g., corticosteroids, immunosuppressant, etc. or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) within 30 days of the study start and in the discretion of the PI would impact the results of the study. Steroid treatments that would not be expected to impact study results could include steroid inhaler, nasal spray, eyedrops, topical creams used in areas outside of the face, or transient oral dose of steroids to treat acute conditions (eg pulsed oral dose for respiratory airway constriction or skin rash)
14. Individuals with a history of documented keloid scar formation, prominent skin lesions or scars that would render data collection and aesthetic evaluation impossible. The investigator will make that determination based on examining other scars and reviewing any history of treatment for keloid lesions.
15. Individuals with a diagnosis of diabetes
16. Subject participating in another interventional clinical trial assessing treatments that may interfere with the accuracy of data collection for this study within 1 month of Visit 1
17. The inability to obtain sufficient fat from the donor site during the harvest to allow the autologous fat tissue processing prior to facial injection.
2. Any medical condition that would preclude safe administration of anesthesia and safe conduct of the adipose harvest procedure (such as an uncontrolled bleeding disorder or severe pulmonary disease), per investigator discretion.
3. Active infection on the face (e.g., acne, HSV (herpes simplex), etc.,) per investigator discretion.
4. Female in pregnancy (positive pregnancy-test performed before inclusion) or lactation or without effective contraception)
5. Received laser, IPL, botox (6 months), injectable fillers or other surgical cosmetic procedures on the face within 12 months of study consent and screening date. -prohibited for 6 months
6. Acutane use within past 12 months
7. Individuals with any contraindications of autologous lipografting, such as cutaneous rashes or infection in the area of intended fat harvest, lack of available donor fat, or other factors that, in the determination of the investigator, would be considered a contraindication.
8. Individuals diagnosed with known allergies to skin care products, topical antibiotics, adhesives, bandages, lidocaine, epinephrine, or other agents that might be used in the study
9. Individuals with any disease state or inappropriate physical skin condition (e.g., active/history of psoriasis, active eczema, excessive hair, scars, tattoos, etc. on face) that might impair evaluations or increase the health risk to the subject by participation in the opinion of the Investigator
10. Individuals with a history of immunosuppression/immune deficiency disorders/ known or suspected defect of healing (including HIV infection or AIDS)
11. Individuals with an uncontrolled disease such as hypertension, hyperthyroidism, or hypothyroidism, which may impact safety. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, which in the opinion of the Investigator, may create safety concerns or interfere with the study.
12. Individuals currently taking substances known to affect bleeding time, which in the opinion of the Investigator, may create safety concerns or interfere with the study (e.g., aspirin, Heparin, Warfarin, Plavix, supplements, etc.).
13. Individuals currently and chronically taking substances known to impair the immune system at doses anticipate to have a systemic effect on wound healing (e.g., corticosteroids, immunosuppressant, etc. or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) within 30 days of the study start and in the discretion of the PI would impact the results of the study. Steroid treatments that would not be expected to impact study results could include steroid inhaler, nasal spray, eyedrops, topical creams used in areas outside of the face, or transient oral dose of steroids to treat acute conditions (eg pulsed oral dose for respiratory airway constriction or skin rash)
14. Individuals with a history of documented keloid scar formation, prominent skin lesions or scars that would render data collection and aesthetic evaluation impossible. The investigator will make that determination based on examining other scars and reviewing any history of treatment for keloid lesions.
15. Individuals with a diagnosis of diabetes
16. Subject participating in another interventional clinical trial assessing treatments that may interfere with the accuracy of data collection for this study within 1 month of Visit 1
17. The inability to obtain sufficient fat from the donor site during the harvest to allow the autologous fat tissue processing prior to facial injection.
Minimum Eligible Age
35 Years
Maximum Eligible Age
70 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pittsburgh
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
J. Peter Rubin, MD
UPMC Endowed Professor and Chair of Plastic Surgery
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
J. Peter Rubin, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Patsy Simon, BS, RN, CCRC, CCRA, ACRP-PM
Role: STUDY_DIRECTOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UPMC Aesthetic Plastic Surgery Center
Pittsburgh, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Mojallal A, Lequeux C, Shipkov C, Breton P, Foyatier JL, Braye F, Damour O. Improvement of skin quality after fat grafting: clinical observation and an animal study. Plast Reconstr Surg. 2009 Sep;124(3):765-774. doi: 10.1097/PRS.0b013e3181b17b8f.
Reference Type
BACKGROUND
Khouri RK Jr, Khouri RE, Lujan-Hernandez JR, Khouri KR, Lancerotto L, Orgill DP. Diffusion and perfusion: the keys to fat grafting. Plast Reconstr Surg Glob Open. 2014 Oct 7;2(9):e220. doi: 10.1097/GOX.0000000000000183. eCollection 2014 Sep.
Reference Type
BACKGROUND
Xue EY, Narvaez L, Chu CK, Hanson SE. Fat Processing Techniques. Semin Plast Surg. 2020 Feb;34(1):11-16. doi: 10.1055/s-0039-3402052. Epub 2020 Feb 15.
Reference Type
BACKGROUND
Strong AL, Cederna PS, Rubin JP, Coleman SR, Levi B. The Current State of Fat Grafting: A Review of Harvesting, Processing, and Injection Techniques. Plast Reconstr Surg. 2015 Oct;136(4):897-912. doi: 10.1097/PRS.0000000000001590.
Reference Type
BACKGROUND
Plastic Surgery Statistics. Plastic surgery procedural statistics from the American Society of Plastic Surgeons. Accessed January 21, 2022. https://www.plasticsurgery.org/news/plastic-surgery-statistics
Reference Type
BACKGROUND
Wollina U, Wetzker R, Abdel-Naser MB, Kruglikov IL. Role of adipose tissue in facial aging. Clin Interv Aging. 2017 Dec 6;12:2069-2076. doi: 10.2147/CIA.S151599. eCollection 2017.
Reference Type
BACKGROUND
Egro FM, Coleman SR. Facial Fat Grafting: The Past, Present, and Future. Clin Plast Surg. 2020 Jan;47(1):1-6. doi: 10.1016/j.cps.2019.08.004. Epub 2019 Oct 21.
Reference Type
BACKGROUND
Schultz KP, Raghuram A, Davis MJ, Abu-Ghname A, Chamata E, Rohrich RJ. Fat Grafting for Facial Rejuvenation. Semin Plast Surg. 2020 Feb;34(1):30-37. doi: 10.1055/s-0039-3402767. Epub 2020 Feb 15.
Reference Type
BACKGROUND
Marten T, Elyassnia D. Facial Fat Grafting: Why, Where, How, and How Much. Aesthetic Plast Surg. 2018 Oct;42(5):1278-1297. doi: 10.1007/s00266-018-1179-x. Epub 2018 Aug 31.
Reference Type
BACKGROUND
Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):108S-120S. doi: 10.1097/01.prs.0000234610.81672.e7.
Reference Type
BACKGROUND
Evans BGA, Gronet EM, Saint-Cyr MH. How Fat Grafting Works. Plast Reconstr Surg Glob Open. 2020 Jul 14;8(7):e2705. doi: 10.1097/GOX.0000000000002705. eCollection 2020 Jul.
Reference Type
BACKGROUND
Tonnard P, Verpaele A, Peeters G, Hamdi M, Cornelissen M, Declercq H. Nanofat grafting: basic research and clinical applications. Plast Reconstr Surg. 2013 Oct;132(4):1017-1026. doi: 10.1097/PRS.0b013e31829fe1b0.
Reference Type
BACKGROUND
Kling RE, Mehrara BJ, Pusic AL, Young VL, Hume KM, Crotty CA, Rubin JP. Trends in autologous fat grafting to the breast: a national survey of the american society of plastic surgeons. Plast Reconstr Surg. 2013 Jul;132(1):35-46. doi: 10.1097/PRS.0b013e318290fad1.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY21110089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Feasibility Study: Treatment of Post-surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ulthera Treatment
NCT01708252
COMPLETED
NA
Autologous Fibroblast Grafts in Facial Skin Regeneration
NCT01490554
UNKNOWN
NA
Evaluation of the Efficacy and Tolerability of Autologous Adipose Tissue Derived Stem Cells on Facial Rejuvenation
NCT03928444
COMPLETED
NA
Lifting and Tightening of the Face and Neck Following an Increased Density Treatment
NCT01519206
COMPLETED
NA
Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face
NCT05355454
COMPLETED
NA
Collagen Injections for the Treatment of Acne Scars and Wrinkles
NCT01704209
TERMINATED
PHASE1
VASER-Assisted Lipoplasty Compared With Suction-Assisted Lipoplasty
NCT00731354
COMPLETED
PHASE4
Autologous Fat Grafting to the Face With Use of the Viality™ System
NCT06169670
RECRUITING
NA
Bipolar RF Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue and Effect on Elastin
NCT04245696
WITHDRAWN
NA
Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars
NCT03050723
COMPLETED
NA
Facial Yoga Toning Program - A Pilot Study
NCT00952549
WITHDRAWN
EARLY_PHASE1
Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis
NCT02655042
WITHDRAWN
Effect of Platelet Rich Plasma on Photoaged Skin
NCT01372566
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells
NCT01828723
COMPLETED
PHASE1
Use of AAM for Correction of Age Related Volume Deficits in the Face
NCT03652844
COMPLETED
NA
Stromal Vascular Fraction Enriched PRP in Treatment of Post-acne Scars
NCT06524011
NOT_YET_RECRUITING
NA
Clinical Study To Assess The Safety, Parameters And Efficacy For Procedures Using A Radiofrequency Device
NCT05166824
COMPLETED
NA
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
NCT05254210
COMPLETED
NA
Split Face Study of the Effects of Micro Needling With and Without Platelet Rich Plasma
NCT04219293
TERMINATED
NA
Fat Grafting an Ideal Filler For Contour Deformities With Hyperpigmentation On Face
NCT06103461
COMPLETED
NA
Face Transplantation Clinical Trial
NCT01269164
COMPLETED
NA
Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty
NCT00958425
WITHDRAWN
PHASE3
Injectable Poly-L-Lactic Acid for Volumization and Adipogenesis of the Hip Dell
NCT05269654
UNKNOWN
NA
Gene Expression Following Ultherapy® Treatment
NCT02441036
TERMINATED
NA
Feasibility Study: Histological Characterization After Treatment With the Ulthera® System
NCT01713569
TERMINATED
NA